You are here
Wednesday, February 15, 2006
Study Sheds Light on Effectiveness of Glucosamine and Chondroitin for Painful Knee Osteoarthritis
NCCAM and NIAMS To Hold Telephone Briefing To Release Final GAIT Results.
A telephone briefing to release final results of the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) — a large, phase III, randomized, controlled clinical trial of glucosamine and chondroitin together or alone for osteoarthritis of the knee. During the briefing, the Principal Investigator will share results of the trial and answer questions during a moderated question-and-answer session. The study was funded by the National Center for Complementary and Alternative Medicine (NCCAM) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), both components of the National Institutes of Health.
Telebriefing participants will include:
Stephen E. Straus, M.D., Director, NCCAM
Daniel O. Clegg, M.D., Principal Investigator, Professor of Medicine and Chief of Rheumatology, University of Utah School of Medicine
Marguerite A. Klein, M.S., GAIT Program Officer and co-author, NCCAM
Susana Serrate-Sztein, Ph.D., GAIT Program Officer, NIAMS
Wednesday, February 22, 2006
12:00 p.m., ET
This telebriefing is for credentialed media only. The information will be embargoed until 5:00 p.m. ET, February 22, 2006. Credentialed members of the media interested in telebriefing call-in details should RSVP by Monday, February 20, 2006, by calling 202-745-5051 or e-mailing firstname.lastname@example.org.
The National Center for Complementary and Alternative Medicine’s mission is to explore complementary and alternative medical practices in the context of rigorous science, train CAM researchers, and disseminate authoritative information to the public and professionals. For additional information, call NCCAM’s Clearinghouse toll free at 1-888-644-6226, or visit the NCCAM Web site www.nccam.nih.gov. NCCAM is 1 of 27 institutes and centers at the National Institutes of Health, the Federal focal point for medical research in the United States.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, a component of the National Institutes of Health, DHHS, supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For additional information, call NIAMS’s clearinghouse at (301) 495-4484 or visit NIAMS’s Web site at www.niams.nih.gov.
The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®